Predictive pathology in routine diagnostics of solid tumors

Histology and Histopathology

Volumn 27, Issue 3, 2012, Pages 289-296

  Lassmann, Silke ^a   Werner, Martin ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Molecular; Pathology; Predictive markers; Solid tumors

Indexed keywords

TUMOR MARKER;

BIOPSY; CHEMISTRY; DIAGNOSTIC TEST; GENETICS; HUMAN; MOLECULAR DIAGNOSIS; NEOPLASM; PATHOLOGY; PATIENT SELECTION; PERSONALIZED MEDICINE; PREDICTIVE VALUE; PROGNOSIS; REVIEW; SIGNAL TRANSDUCTION; WORKFLOW;

BIOPSY; DIAGNOSTIC TESTS, ROUTINE; HUMANS; INDIVIDUALIZED MEDICINE; MOLECULAR DIAGNOSTIC TECHNIQUES; NEOPLASMS; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL; WORKFLOW;

EID: 84857696767     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. Allegra C.J., Jessup J.M., Somerfield M.R., Hamilton S.R., Hammond E.H., Hayes D.F., McAllister P.K., Morton R.F. and Schilsky R.L. (2009). American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J. Clin. Oncol. 27, 2091-2096.
2. Antonescu C.R. (2009). The GIST paradigm: lessons for other kinasedriven cancers. J. Pathol. 223, 251-261.
3. Banck M.S. and Grothey A. (2009). Biomarkers of resistance to epidermal growth factor receptor monoclonal antibodies in patients with metastatic colorectal cancer. Clin. Cancer. Res. 15, 7492-7501.
4. Bollag G., Hirth P., Tsai J., Zhang J., Ibrahim P.N., Cho H., Spevak W., Zhang C., Zhang Y., Habets G., Burton E.A., Wong B., Tsang G., West B.L., Powell B., Shellooe R., Marimuthu A., Nguyen H., Zhang K.Y., Artis D.R., Schlessinger J., Su F., Higgins B., Iyer R., D'Andrea K., Koehler A., Stumm M., Lin P.S., Lee R.J., Grippo J., Puzanov I., Kim K.B., Ribas A., McArthur G.A., Sosman J.A., Chapman P.B., Flaherty K.T., Xu X., Nathanson K.L. and Nolop K. (2010). Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAFmutant melanoma. Nature 467, 596-599.
5. Camidge D.R., Kono S.A., Lu X., Okuyama S., Barón A.E., Oton A.B., Davies A.M., Varella-Garcia M., Franklin W. and Doebele R.C. (2011). Anaplastic Lymphoma Kinase Gene Rearrangements in Non-small Cell Lung Cancer are Associated with Prolonged Progression-Free Survival on Pemetrexed. J. Thorac. Oncol. 6, 774-780.
6. Cataldo K.A., Jalal S.M., Law M.E., Ansell S.M., Inwards D.J., Fine M., Arber D.A., Pulford K.A. and Strickler J.G. (1999). Detection of t(2;5) in anaplastic large cell lymphoma: comparison of immunohistochemical studies, FISH, and RT-PCR in paraffin-embedded tissue. Am. J. Surg. Pathol. 23, 1386-1392.
7. Chung K.Y., Shia J., Kemeny N.E., Shah M., Schwartz G.K., Tse A., Hamilton A., Pan D., Schrag D., Schwartz L., Klimstra D.S., Fridman D., Kelsen D.P. and Saltz L.B. (2005). Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J. Clin. Oncol. 23, 1803-1810.
8. Cunningham D., Humblet Y., Siena S., Khayat D., Bleiberg H., Santoro A., Bets D., Mueser M., Harstrick A., Verslype C., Chau I. and Van Cutsem E. (2004). Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 351, 337-345.
9. Curtin J.A., Fridlyand J., Kageshita T., Patel H.N., Busam K.J., Kutzner H., Cho K.H., Aiba S., Bröcker E.B., LeBoit P.E., Pinkel D. and Bastian B.C. (2005). Distinct sets of genetic alterations in melanoma. N. Engl. J. Med. 353, 2135-2147.
10. Curtin J.A., Busam K., Pinkel D. and Bastian B.C. (2006). Somatic activation of KIT in distinct subtypes of melanoma. J. Clin. Oncol. 24, 4340-4346.
11. Ellerhorst J.A., Greene V.R., Ekmekcioglu S., Warneke C.L., Johnson M.M., Cooke C.P., Wang L.E., Prieto V.G., Gershenwald J.E., Wei Q. and Grimm E.A. (2011). Clinical correlates of NRAS and BRAF mutations in primary human melanoma. Clin. Cancer. Res. 17, 229-235.
12. Franklin W.A., Haney J., Sugita M., Bemis L., Jimeno A. and Messersmith W.A. (2010). KRAS mutation: comparison of testing methods and tissue sampling techniques in colon cancer. J. Mol. Diagn. 12, 43-50.
13. Griffin C.A., Hawkins A.L., Dvorak C., Henkle C., Ellingham T. and Perlman E.J. (1999). Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors. Cancer Res. 59, 2776-2780.
14. Gruver A.M., Peerwani Z. and Tubbs R.R. (2010). Out of the darkness and into the light: bright field in situ hybridisation for delineation of ERBB2 (HER2) status in breast carcinoma. J. Clin. Pathol. 63, 210-219.
15. Hammerman P.S., Jänne P.A. and Johnson B.E. (2009). Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer. Clin. Cancer Res. 15, 7502-7509.
16. Hicks D.G. and Tubbs R.R. (2005). Assessment of the HER2 status in breast cancer by fluorescence in situ hybridization: a technical review with interpretive guidelines. Hum. Pathol. 36, 250-261.
17. Hicks D.G., Yoder B.J., Pettay J., Swain E., Tarr S., Hartke M., Skacel M., Crowe J.P., Budd G.T. and Tubbs R.R. (2005). The incidence of topoisomerase II-alpha genomic alterations in adenocarcinoma of the breast and their relationship to human epidermal growth factor receptor-2 gene amplification: a fluorescence in situ hybridization study. Hum. Pathol. 36, 348-356.
18. Hodi F.S., Friedlander P., Corless C.L., Heinrich M.C., Mac Rae S., Kruse A., Jagannathan J., Van den Abbeele A.D., Velazquez E.F., Demetri G.D. and Fisher D.E. (2008). Major response to imatinib mesylate in KIT-mutated melanoma. J. Clin. Oncol. 26, 2046-2051.
19. Italiano A., Follana P., Caroli F.X., Badetti J.L., Benchimol D., Garnier G., Gugenheim J., Haudebourg J., Keslair F., Lesbats G., Lledo G., Roussel J.F., Pedeutour F. and François E. (2008) Cetuximab shows activity in colorectal cancer patients with tumors for which FISH analysis does not detect an increase in EGFR gene copy number. Ann. Surg. Oncol. 15, 649-654.
20. Jones K.L. and Buzdar A.U. (2009). Evolving novel anti-HER2 strategies. Lancet Oncol. 10, 1179-1187.
21. Kwak E.L., Bang Y.J., Camidge D.R., Shaw A.T., Solomon B., Maki R.G., Ou S.H., Dezube B.J., Jänne P.A., Costa D.B., Varella-Garcia M., Kim W.H., Lynch T.J., Fidias P., Stubbs H., Engelman J.A., Sequist L.V., Tan W., Gandhi L., Mino-Kenudson M., Wei G.C., Shreeve S.M., Ratain M.J., Settleman J., Christensen J.G., Haber D.A., Wilner K., Salgia R., Shapiro G.I., Clark J.W. and Iafrate A.J. (2010). Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 363, 1693-1703.
22. Lassmann S., Kreutz C., Schoepflin A., Hopt U., Timmer J. and Werner M. (2009). A novel approach for reliable microarray analysis of microdissected tumor cells from formalin-fixed and paraffinembedded colorectal cancer resection specimens. J. Mol. Med. 87, 211-224.
23. Larsson C., Grundberg I., Söderberg O. and Nilsson M. (2010). In situ detection and genotyping of individual mRNA molecules. title typejournalNat. Methods/title 7, 395-397.
24. Lawrence B., Perez-Atayde A., Hibbard M.K., Rubin B.P., Dal Cin P., Pinkus J.L., Pinkus G.S., Xiao S., Yi E.S., Fletcher C.D. and Fletcher J.A. (2000). TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors. Am. J. Pathol. 157, 377-384.
25. Lee J.H., Choi J.W. and Kim Y.S. (2010). Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis. Br. J. Dermatol. 164, 776-784.
26. Liegl-Atzwanger B., Fletcher J.A. and Fletcher C.D. (2010). Gastrointestinal stromal tumors. Virchows Arch. 456, 111-127.
27. Martelli M.P., Sozzi G., Hernandez L., Pettirossi V., Navarro A., Conte D., Gasparini P., Perrone F., Modena P., Pastorino U., Carbone A., Fabbri A., Sidoni A., Nakamura S., Gambacorta M., Fernández P.L., Ramirez J., Chan J.K., Grigioni W.F., Campo E., Pileri S.A. and Falini B. (2009). EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues. Am. J. Pathol. 174, 661-670.
28. McArthur G.A., Demetri G.D., van Oosterom A., Heinrich M.C., Debiec Rychter M., Corless C.L., Nikolova Z., Dimitrijevic S. and Fletcher J.A. (2005). Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225. J. Clin. Oncol. 23, 866-873.
29. Mino-Kenudson M., Chirieac L.R., Law K., Hornick J.L., Lindeman N., Mark E.J., Cohen D.W., Johnson B.E., Jänne P.A., Iafrate A.J. and Rodig S.J. (2010). A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. Clin. Cancer Res. 16, 1561-1571.
30. Nazarian R., Shi H., Wang Q., Kong X., Koya R.C., Lee H., Chen Z., Lee M.K., Attar N., Sazegar H., Chodon T., Nelson S.F., McArthur G., Sosman J.A., Ribas A. and Lo R.S. (2010). Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468, 973-977.
31. Ordóñez J.L., Osuna D., García-Domínguez D.J., Amaral A.T., Otero Motta A.P., Mackintosh C., Sevillano M.V., Barbado M.V., Hernández T. and de Alava E. (2010). The clinical relevance of molecular genetics in soft tissue sarcomas. Adv. Anat. Pathol. 17, 162-181.
32. Pao W. and Chmielecki J. (2010). Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat. Rev. Cancer 10, 760-774.
33. Pirker R., Herth F.J., Kerr K.M., Filipits M., Taron M., Gandara D., Hirsch F.R., Grunenwald D., Popper H., Smit E., Dietel M., Marchetti A., Manegold C., Schirmacher P., Thomas M., Rosell R., Cappuzzo F. and Stahel R; European EGFR Workshop Group (2010) Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop. J. Thorac. Oncol. 5, 1706-1713.
34. Pohlmann P.R., Mayer I.A. and Mernaugh R. (2009). Resistance to Trastuzumab in Breast Cancer. Clin. Cancer Res. 15, 7479-7491.
35. Roberts P.J., Stinchcombe T.E., Der C.J. and Socinski M.A. (2010). Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy? J. Clin. Oncol. 28, 4769-4777.
36. Rosen L.S., Ashurst H.L. and Chap L. (2010). Targeting signal transduction pathways in metastatic breast cancer: a comprehensive review. Oncologist 15, 216-235.
37. Rüschoff J., Dietel M., Baretton G., Arbogast S., Walch A., Monges G., Chenard M.P., Penault-Llorca F., Nagelmeier I., Schlake W., Höfler H. and Kreipe H.H. (2010). HER2 diagnostics in gastric cancerguideline validation and development of standardized immunohistochemical testing. Virchows Arch. 457, 299-307.
38. Saltz L.B., Meropol N.J., Loehrer P.J., Needle M.N., Kopit J. and Mayer R.J. (2004). Phase II trial of Cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J. Clin. Oncol. 22, 1201-1208.
39. Sarasqueta A., Moerland E., de Bruyne H., de Graaf H., Vrancken T., van Lijnschoten G. and van den Brule A.J. (2011). SNaPshot and StripAssay as valuable alternatives to direct sequencing for KRAS mutation detection in colon cancer routine diagnostics. J. Mol. Diagn. 13, 199-205.
40. Segura S., Salgado R., Toll A., Martín-Ezquerra G., Yébenes M., Sáez A., Solé F., Barranco C., Umbert P., Espinet B. and Pujol R.M. (2011). Identification of t(17;22)(q22;q13) (COL1A1/PDGFB) in dermatofibrosarcoma protuberans by fluorescence in situ hybridization in paraffin-embedded tissue microarrays. Hum. Pathol. 42, 176-184.
41. Shaw A.T., Yeap B.Y., Mino-Kenudson M., Digumarthy S.R., Costa D.B., Heist R.S., Solomon B., Stubbs H., Admane S., McDermott U., Settleman J., Kobayashi S., Mark E.J., Rodig S.J., Chirieac L.R., Kwak E.L., Lynch T.J. and Iafrate A.J. (2009). Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J. Clin. Oncol. 27, 4247-4253.
42. Soda M., Choi Y.L., Enomoto M., Takada S., Yamashita Y., Ishikawa S., Fujiwara S., Watanabe H., Kurashina K., Hatanaka H., Bando M., Ohno S., Ishikawa Y., Aburatani H., Niki T., Sohara Y., Sugiyama Y. and Mano H. (2007). Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448, 561-566.
43. Takeuchi K., Choi Y.L., Togashi Y., Soda M., Hatano S., Inamura K., Takada S., Ueno T., Yamashita Y., Satoh Y., Okumura S., Nakagawa K., Ishikawa Y. and Mano H. (2009). KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin. Cancer Res. 15, 3143-3149.
44. van Krieken J.H., Jung A., Kirchner T., Carneiro F., Seruca R., Bosman F.T., Quirke P., Fléjou J.F., Plato Hansen T., de Hertogh G., Jares P., Langner C., Hoefler G., Ligtenberg M., Tiniakos D., Tejpar S., Bevilacqua G. and Ensari A. (2008). KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program. Virchows Arch. 453, 417-431.
45. Voelkerding K.V., Dames S. and Durtschi J.D. (2010). Next generation sequencing for clinical diagnostics-principles and application to targeted resequencing for hypertrophic cardiomyopathy: a paper from the 2009 William Beaumont Hospital Symposium on Molecular Pathology. J. Mol. Diagn. 12, 539-551.
46. Wardelmann E., Schildhaus H.U., Merkelbach-Bruse S., Hartmann W., Reichardt P., Hohenberger P. and Büttner R. (2010). Soft tissue sarcoma: from molecular diagnosis to selection of treatment. Pathological diagnosis of soft tissue sarcoma amid molecular biology and targeted therapies. Ann. Oncol. 21 (Suppl 7), vii265-vii269.
47. Weichert W., Schewe C., Lehmann A., Sers C., Denkert C., Budczies J., Stenzinger A., Joos H., Landt O., Heiser V., Röcken C. and Dietel M. (2010). KRAS genotyping of paraffin-embedded colorectal cancer tissue in routine diagnostics: comparison of methods and impact of histology. J. Mol. Diagn. 12, 35-42.
48. Wellstein A. and Toretsky J.A. (2011). Hunting ALK to feed targeted cancer therapy. Nat. Med. 17, 290-291.
49. Woodman S.E., Trent J.C., Stemke-Hale K., Lazar A.J., Pricl S., Pavan G.M., Fermeglia M., Gopal Y.N., Yang D., Podoloff D.A., Ivan D., Kim K.B., Papadopoulos N., Hwu P., Mills G.B. and Davies M.A. (2009). Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates. Mol. Cancer Ther. 8, 2079-2085.